# Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer

> **NCT07014410** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pyrotinib dalpiciclib letrozole

## Key facts

- **NCT ID:** NCT07014410
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014410, "Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07014410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*